

Video Article

In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model

Debabrata Saha¹, Henry Dunn², Heling Zhou², Hiroshi Harada³, Masahiro Hiraoka³, Ralph P. Mason², Dawen Zhao²

¹Department of Radiation Oncology, University of Texas Southwestern Medical Center

²Department of Radiology, University of Texas Southwestern Medical Center

³Department of Radiation Oncology, Kyoto University Graduate School of Medicine

Correspondence to: Dawen Zhao at Dawen.Zhao@UTSouthwestern.edu

URL: <http://www.jove.com/details.php?id=3175>

DOI: 10.3791/3175

Keywords: Medicine, Issue 56, bioluminescence imaging (BLI), tumor hypoxia dynamics, hypoxia inducible factor-1α (HIF-1α), breast cancer brain metastasis,

Date Published: 10/3/2011

Citation: Saha, D., Dunn, H., Zhou, H., Harada, H., Hiraoka, M., Mason, R.P., Zhao, D. In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model. J. Vis. Exp. (56), e3175, DOI : 10.3791/3175 (2011).

Abstract

It is well recognized that tumor hypoxia plays an important role in promoting malignant progression and affecting therapeutic response negatively. There is little knowledge about *in situ*, *in vivo*, tumor hypoxia during intracranial development of malignant brain tumors because of lack of efficient means to monitor it in these deep-seated orthotopic tumors. Bioluminescence imaging (BLI), based on the detection of light emitted by living cells expressing a luciferase gene, has been rapidly adopted for cancer research, in particular, to evaluate tumor growth or tumor size changes in response to treatment in preclinical animal studies. Moreover, by expressing a reporter gene under the control of a promoter sequence, the specific gene expression can be monitored non-invasively by BLI. Under hypoxic stress, signaling responses are mediated mainly via the hypoxia inducible factor-1α (HIF-1α) to drive transcription of various genes. Therefore, we have used a HIF-1α reporter construct, 5HRE-ODD-luc, stably transfected into human breast cancer MDA-MB231 cells (MDA-MB231/5HRE-ODD-luc). *In vitro* HIF-1α bioluminescence assay is performed by incubating the transfected cells in a hypoxic chamber (0.1% O₂) for 24 hr before BLI, while the cells in normoxia (21% O₂) serve as a control. Significantly higher photon flux observed for the cells under hypoxia suggests an increased HIF-1α binding to its promoter (HRE elements), as compared to those in normoxia. Cells are injected directly into the mouse brain to establish a breast cancer brain metastasis model. *In vivo* bioluminescence imaging of tumor hypoxia dynamics is initiated 2 wks after implantation and repeated once a week. BLI reveals increasing light signals from the brain as the tumor progresses, indicating increased intracranial tumor hypoxia. Histological and immunohistochemical studies are used to confirm the *in vivo* imaging results. Here, we will introduce approaches of *in vitro* HIF-1α bioluminescence assay, surgical establishment of a breast cancer brain metastasis in a nude mouse and application of *in vivo* bioluminescence imaging to monitor intracranial tumor hypoxia.

Video Link

The video component of this article can be found at <http://www.jove.com/details.php?id=3175>

Protocol

All animal procedures were approved by the Institutional Animal Care and Use Committee of University of Texas Southwestern Medical Center.

1. *In vitro* HIF-1α bioluminescence assay

1. Materials and Methods:

- Human metastatic breast cancer cell line MDA-MB231 transfected with a novel HIF-1-dependent reporter gene, 5HRE-ODD-luc was generated by Dr. Harada.
- In hypoxic condition, the enhanced expression of oxygen-dependent degradation domain (ODD)-Luciferase fusion protein is driven by 5 copies of hypoxia-response element (5HRE). The presence of ODD causes the degradation of ODD-Luc protein resulting in extremely low background luciferase activity in normoxic conditions. Therefore, this novel system can be used to detect hypoxic regions in a tumor by real time imaging. The construction of this 5HRE-ODD-luc expression vector has been reported by Harada et al^{1,2}.

2. Culture cells under normoxia or hypoxia:

- Maintain the recombinant MDA-MB231 cells in 10% fetal bovine serum (FBS)-DMEM medium containing 1% glutamine, antibiotics of 400 µg/ml of G418 and 1% penicillin/streptomycin.
- For the *in vitro* HIF-1α bioluminescence assay, plate 3 x 10⁵ MDA-MB231 cells expressing 5HRE-ODD-luc vector in each well of two six well dish.
- Allow cells to attach the dish wall after overnight incubation and then transfer one dish into a hypoxia chamber (Billups-Rothenberg, Inc. Del Mar, CA) for hypoxia studies, while keep the other dish under normoxic condition (21% O₂).
- Reassemble the chamber and gas the chamber with 0.1% O₂ by connecting the inlet port tubing with a gas cylinder.

Note: Both inlet and outlet port clamps must be open during this procedure.

- Disconnect gas source after chamber has been purged and seal chamber by closing plastic clamps.

- Place the chamber in a 37 °C incubator with 5% CO₂.

Note: The chamber must be humidified to prevent excessive evaporation of cultures. This can be accomplished by placing 10 - 20 ml sterile water in the chamber.

3. Bioluminescence assay:

- After 24 hr incubation, remove the medium and wash the cells quickly with ice cold PBS (2X).
- Add 1 ml of cold PBS with 100 µl of Luciferin (Gold Biotechnology, St Louis, MO).
- Acquire BL imaging (IVIS Spectrum system, Caliper Life Sciences, Hopkinton, MA) with various exposure times (1, 30, 60, 180 s).
- Measure light intensity in each well using the Living Image software (Caliper Life Sciences).

2. Establishment of a breast cancer brain metastasis model

1. Preparation of the MDA-MB231/5HRE-ODD-luc cells

- Retrieve and culture the MDA-MB231/5HRE-ODD-luc cells in DME medium containing 10% FBS, 1% glutamine and 1% penicillin/streptomycin.
- Replace medium every 2-3 days. Trypsinize and wash the cells when they reach 80% confluence.
- Count appropriate number of cells and resuspend them in serum free DME medium with 25% Matrigel (BD Biosciences, San Jose, CA) with a final concentration of 10⁵ cells in 4 µl volume.
- Place cells on ice prior to intracranial injection.

2. Surgical implantation

- Female nude mice (BALB/c nu/nu; National Cancer Institute, Bethesda, MD) at 4-6 weeks old are used in this study.
- Anesthetize (3% isoflurane/ O₂ in an induction chamber; isoflurane from Baxter International Inc., Deerfield, IL, USA) and maintain the animals with isoflurane (1%) in oxygen (1 dm³/min) during the surgical procedure³.
- The right parietal skin should be prepped with betadine and then 70% alcohol prior to incision.
- Using a high-speed drill, burr a 1 mm hole in the right hemisphere of the skull, 1mm anterior to the coronal suture and 2 mm lateral to sagittal suture.
- Draw 4 µl cell mixture (10⁵ cells) using a 10 µl Hamilton syringe (Hamilton Company, Reno, NV). Inject the cells directly into right caudal diencephalon, 1.5 mm beneath the dura mater using a custom-made 32G Hamilton needle. Keep the needle in place for about 30 s before withdrawal. Usage of a 32G fine needle minimizes tissue damage.
- Fill the burr hole with bone wax and close the scalp with absorbable sutures.
- Prepare the incision region with 70% alcohol.
- Apply buprenorphine analgesia every 12 hrs for two days.

3. *In vivo* bioluminescence imaging of tumor hypoxia dynamics in breast cancer brain metastasis

- Initiate longitudinal bioluminescence imaging (IVIS Spectrum system) two weeks after intracranial implantation and repeat once a week for 8-10 weeks.
- Anesthetize three mice at a time (3% isoflurane/ O₂ in an induction chamber)
- Administer a solution of D-luciferin (120 mg/kg in PBS in a total volume of 80 µl; Gold Biotechnology) subcutaneously in the neck region of each mouse as described in detail previously⁴.

D-luciferin is non-toxic and has been shown to be capable of penetrating intact blood-brain barrier (BBB) and cell membranes^{3,5}.

- Place the 3 mice in the imaging chamber and maintained with isoflurane (1%) in oxygen (1 dm³/min) during imaging.
- Five minutes after luciferin injection, acquire BL imaging with an array of various exposure time (1, 30, 60, 180 s).

Our observations show that the peak light emission time is about 5 mins after subcutaneous administration of luciferin in the neck region^{3,4}.

- Analyze data with the Living Imaging software (Caliper Life Sciences) by using absolute photon counts (photons/s) in a region of interest (ROI), manually drawn to outline the BLI signal of the brain.
- Plot time course curve of photon counts to indicate tumor hypoxia dynamics.
- Immediately after the last BLI, administer pimonidazole, the hypoxia marker and 1 hr later, sacrifice the mice and dissect the brains. Embed the whole brains in Optimal Cutting Temperature (O.C.T.) medium and freeze in -80 °C freezer. Subsequent histological Cresyl violet staining and immunohistochemical staining against luciferase, hypoxia marker pimonidazole, and HIF-1α performed to validate imaging observations.

4. Representative results:

As shown in Fig. 1, significantly higher BLI signal was observed after the transfected cells incubated in the hypoxic chamber (1% O₂) for 24 hrs. Weak light emission was observed from the control cells under normoxia. This may result from the overcrowded cell population after 24 hr culture of 3 x 10⁵ cells, which induced a stress signal to the cells to overexpress HIF-1α. Nonetheless, *in vivo* BLI results were validated by immunohistochemical staining showing colocalization between tumor hypoxia and luciferase expression.

An automated array of exposure times enables continuous acquisitions of a series of images, which facilitates capture of a weak signal with longer exposure time, and strong signals using a shorter time without saturating the CCD.




Figure 1 *In vitro* HIF-1 α bioluminescence assay. **Top row:** 3×10^5 MDA-MB231/5HRE-ODD-luc cells incubated in each well of a 6-well-dish in a hypoxia chamber (0.1% O₂) for 24 hr before the medium was removed, washed and replaced with 1 ml PBS. Immediately after 100 μ l luciferin was added into each well, BLI was acquired with an array of exposure times (1, 30, 60, 180 s). Strong luminescence was observed from representative wells. **Bottom row:** As a control, 3×10^5 cells incubated under normoxia (21% O₂) emitted weak light.




Figure 2 *In vivo* bioluminescence imaging of tumor hypoxia dynamics. **A)** A weak light signal from right side of mouse brain was first visualized 5 weeks after intracranial implantation of MDA-MB231/5HRE-ODD-luc breast cancer cells. Increased optical signal was observed over additional 6 weeks, indicating increased tumor hypoxia. **B)** The plot showed the time course curve of quantitative photon counts of light signal.




Figure 3 Colocalization of luciferase and hypoxia detected by immunohisto-chemical staining. A frozen mouse brain bearing a metastasis of breast cancer MDA-MB231/5HRE-ODD-luc embedded in O.C.T. was sectioned. A 10 μ m section immunostained with hypoxic marker, pimonidazole, revealed intratumoral heterogeneity of hypoxia, which was found to correlate spatially with luciferase expression detected by anti-luciferase staining. Scale bar, 100 μ m.

Discussion

Breast cancer brain metastasis occurs in 30% of breast cancer patients at stage IV. It is associated with high morbidity and mortality and has a median survival of 13 months⁶. There is a need to have appropriate animal models to mimic this clinically devastating disease in order to facilitate our understanding of its intracranial initiation and progression as well as pathophysiological profiles. Here, we have developed an orthotopic breast cancer brain metastasis model by injecting human breast cancer cells, directly into mouse brain. Our previous experiences have shown that a radiologically visualized (by MRI) intracranial lesion appears approximately 2 weeks after implantation. Alternative to this direct injection model, we have recently implemented an intracardiac cell injection approach to create another orthotopic breast cancer brain metastasis model by injecting cancer cells into the left ventricle of mice. However, pre-selection of brain metastases-prone breast cancer cells is necessary to achieve multi-focal brain lesions in this model⁷. We have recently introduced the same HRE-luc construct into the mouse breast cancer 4T1 cells that are able to metastasize into mouse brain via intracardiac injection.

Bioluminescence imaging is highly sensitive and efficient, which, unlike fluorescence imaging, does not need light excitation. This facilitates imaging of deep-seated tumors in rodent models, *e.g.*, the intracranial brain tumors of mouse in this study. Three or even five mice can be imaged at the same time. However, to increase sensitivity especially when a weak signal was seen on the whole body image, setting the animal position closer to the camera will be necessary. In this case, only one or two animals can be imaged each time. One limitation of BLI is low spatial resolution of the anatomy although there are methods to generate tomographic images. Co-registration with micro-CT or MR images would assist to properly identify the anatomy.

Extensive efforts have been sought to develop non-invasive approaches to monitor tumor hypoxia *in vivo*^{8,9}. By introducing a hypoxia reporter gene into the genome of cancer cells, longitudinal monitoring of tumor hypoxia evolution can be monitored by optical imaging^{10,11}. Similarly, tumor hypoxia dynamics following treatment can be monitored using this approach.

In addition to luciferase and its substrate, luciferin, oxygen and ATP are indispensable elements in the luciferin-luciferase reaction to produce light. In hypoxic environment, availability of oxygen and ATP production may be significantly limited, which could result in reduced light emission. However, our *in vitro* BLI assay showed that the MDA-231/HRE-luc cells incubated under hypoxic condition ($< 0.1\%$ O_2) emitted significantly more light, as compared to those in normoxic condition. Moreover, the immunohistochemical data of tumor tissues revealed a good spatial correlation between luciferase expression and pimonidazole. These observations are in a good agreement with previous studies by others, suggesting that the oxygen concentration and ATP required for efficient light production are well below their levels found in living mammalian cells. We have also combined functional MRI approaches, BOLD (blood oxygen level dependent) and TOLD (tissue oxygen level dependent) MRI to evaluate tumor hypoxia in this model. Comparable data have been obtained from the multimodal imaging approaches (unpublished data). Moreover,

immunohistochemical staining confirmed colocalization of hypoxic tumor cells and luciferase expressing cells. Accurate assessment of baseline tumor hypoxia and the dynamic changes in response to treatment ought to allow rational therapeutic combination¹².

In conclusion, the inexpensive, fast and highly sensitive BLI can be a useful tool to non-invasively assess tumor hypoxia dynamics *in vivo*. While the orthotopic brain tumor model has been used in this study, the methodology can certainly be applied for other types of deep-seated orthotopic tumors in rodents.

Disclosures

No conflicts of interest declared.

Acknowledgements

This study is supported in part by DOD Breast Cancer IDEA Award W81XWH-08-1-0583 and NIH/NCI CA141348-01A1 (DZ) and FAMRI clinical scientist award (DS). Imaging infrastructure is provided by Southwestern Small Animal Imaging Research Program supported in part by U24 CA126608 and Simmons Cancer Center (P30 CA142543) and NIH 1S10RR024757-01.

References

1. Harada, H., *et al.* The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. *Biochem Biophys Res Commun.* **360** (4), 791-796 (2007).
2. Ou, G., *et al.* Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. *Int J Radiat Oncol Biol Phys.* **75** (2), 463-467 (2009).
3. Zhou, H., *et al.* Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. *PLoS One.* **4** (11), e8051 (2009).
4. Contero, A., Richer, E., Gondim, A., & Mason, R.P. High-throughput quantitative bioluminescence imaging for assessing tumor burden. *Methods Mol Biol.* **574**, 37-45 (2009).
5. Zhao, D., Richer, E., Antich, P.P., & Mason, R.P. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. *FASEB J.* **22**, 2245-2451 (2008).
6. Chang, E.L. & Lo, S., Diagnosis and management of central nervous system metastases from breast cancer. *Oncologist.* **8** (5), 398-410 (2003).
7. Palmieri, D., *et al.* Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. *Clin Cancer Res.* **15** (19), 6148-6157 (2009).
8. Mason, R.P., *et al.* Multimodality imaging of hypoxia in preclinical settings. *Q J Nucl Med Mol Imaging.* **54** (3), 259-280 (2010).
9. Tatum, J.L., *et al.* Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. *Int J Radiat Biol.* **82** (10), 699-757 (2006).
10. Moeller, B.J., *et al.* Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. *Cancer Cell.* **8** (2), 99-110 (2005).
11. Lu, X., *et al.* *In vivo* dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. *Cancer Res.* **70** (10), 3905-3914 (2010).
12. Zhao, D., Chang, C.H., Kim, J.G., Liu, H., & Mason, R.P. *In vivo* Near-Infrared Spectroscopy and Magnetic Resonance Imaging Monitoring of Tumor Response to Combretastatin A-4-Phosphate Correlated With Therapeutic Outcome. *Int J Radiat Oncol Biol Phys.* **80** (2), 574-81 (2011).